All > Metastatic Triple Negative Breast Cancer > Paid Studies Connecticut

ladiratuzumab vedotin for Triple Negative Breast Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Triple Negative Breast Cancer+4 Moreladiratuzumab vedotin - Drug
Eligibility
18+
Female
What conditions do you have?
Select

Study Summary

This trial will study the safety and effectiveness of a new cancer drug, given alone or with another drug.

Eligible Conditions
  • Triple Negative Breast Cancer
  • HER2-positive Breast Cancer
  • Hormone Receptor Positive Breast Cancer
  • HER2 Positive Breast Cancer
  • Breast Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Treatment Arm
1
Internet-Based Intervention
1
mRNA-2752

Study Objectives

3 Primary · 7 Secondary · Reporting Duration: Through 3 weeks after dosing; up to approximately 2 years

Year 2
Incidence of adverse events
Incidence of antitherapeutic antibodies
Incidence of laboratory abnormalities
Objective response rate (ORR)
Year 2
Blood concentrations of LV and metabolites
Week 3
Incidence of dose-limiting toxicity (DLT)
Year 3
Duration of response (DOR)
Year 8
Overall survival (OS)
PFS relative to prior therapy
Progression-free survival (PFS)

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
Treatment Arm
1
Internet-Based Intervention
1
mRNA-2752

Trial Design

3 Treatment Groups

LV Dose Escalation
1 of 3
LV Monotherapy
1 of 3
LV + Trastuzumab
1 of 3

Experimental Treatment

290 Total Participants · 3 Treatment Groups

Primary Treatment: ladiratuzumab vedotin · No Placebo Group · Phase 1

LV Dose Escalation
Drug
Experimental Group · 1 Intervention: ladiratuzumab vedotin · Intervention Types: Drug
LV Monotherapy
Drug
Experimental Group · 1 Intervention: ladiratuzumab vedotin · Intervention Types: Drug
LV + TrastuzumabExperimental Group · 2 Interventions: Trastuzumab, ladiratuzumab vedotin · Intervention Types: Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Trastuzumab
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: through 3 weeks after dosing; up to approximately 2 years

Who is running the clinical trial?

Seagen Inc.Lead Sponsor
185 Previous Clinical Trials
61,289 Total Patients Enrolled
Phillip Garfin, MDStudy DirectorSeagen Inc.
Zejing Wang, MD, PhDStudy DirectorSeagen Inc.
2 Previous Clinical Trials
625 Total Patients Enrolled
Kristel Apolinario, PharmDStudy DirectorSeagen Inc.
1 Previous Clinical Trials
211 Total Patients Enrolled
Sinhan Tran, PharmD, MBAStudy DirectorSeagen Inc.
2 Previous Clinical Trials
625 Total Patients Enrolled
Brandon Croft, PharmDStudy DirectorSeagen Inc.
2 Previous Clinical Trials
625 Total Patients Enrolled

Eligibility Criteria

Age 18+ · Female Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have received no prior cytotoxic chemotherapy for unresectable locally advanced or metastatic stage disease.
You have a pathologically confirmed diagnosis of breast cancer with radiographic evidence of LA/MBC.
You have triple negative breast cancer.
Tumor tissue PD-L1 expression CPS <10 expression.
Tumor biopsy must be obtained from a site that is not necessarily surgically accessible.

Who else is applying?

What state do they live in?
New York100.0%
What site did they apply to?
University of California at San Francisco100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%
How many prior treatments have patients received?
3+100.0%
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top